Gilead Announces $5 Billion Share Repurchase Program

-- Provides Update on Buyback Program Initiated in January 2011 --

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 7, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has authorized a repurchase of up to $5 billion of the company’s common stock. This is in addition to a separate $5 billion buyback program announced in January 2011, which has approximately $2.9 billion remaining in the plan and is expected to be completed by September 2014. The new program expires three years after the completion of the current repurchase program.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by Gilead’s management and in accordance with the requirements of the Securities and Exchange Commission.

The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including our ability to consummate repurchases under the share repurchase program due to changes in our stock price, corporate or other market conditions. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy Flood, 650-522-5643 (Media)